T1	intervention 0 11	Palbociclib
T2	eligibility 887 959	women with advanced disease which had progressed on one or two prior ETs
T3	control 1000 1017	palbociclib alone
T4	outcome-Measure 1107 1134	clinical benefit rate (CBR)
T5	outcome-Measure 1166 1197	progression-free survival (PFS)
T6	duration 1199 1233	Between October 2012 and July 2016
T7	No-of-participants 1246 1249	115
T8	outcome 1280 1283	CBR
T9	control-value 1288 1291	54%
T10	intervention-value 1363 1366	60%
T11	outcome 1404 1414	Median PFS
